Bangladesh's Beximco in coronavirus vaccine pact with India's Serum Institute

One of Bangladesh’s largest drugmakers, Beximco Pharmaceuticals, announced on Friday that it will invest with the Serum Institute of India (SII) to ensure Bangladesh gets access to vaccines it is developing for the novel coronavirus. The deal comes after Bangladesh said this month it was ready to hold trials of candidate vaccines developed by India as both countries seek to curb the spread of the virus. “The investment amount will be treated as an advance and once the vaccine receives regulatory approvals, SII will include Bangladesh among the countries who will be the first to receive an agreed quantity of this vaccine from SII on a priority basis,” Beximco said in a statement, citing the heads of both organisations. Beximco will also be the exclusive supplier for Bangladesh for a vaccine developed by the Serum Institute, it said.